{"nctId":"NCT00271219","briefTitle":"RCT Comparing Methadone and Buprenorphine in Pregnant Women","startDateStruct":{"date":"2005-07"},"conditions":["Opioid Related Disorders","Pregnancy","Opioid Dependence"],"count":175,"armGroups":[{"label":"Buprenorphine","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine"]},{"label":"Methadone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Methadone"]}],"interventions":[{"name":"Methadone","otherNames":[]},{"name":"Buprenorphine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Current opioid dependence\n* Current opioid use, as determined by a urine drug test\n* Pregnant with a single child with a gestational age of 6 to 30 weeks, as determined by a sonogram\n\nExclusion Criteria:\n\n* Current medical condition that would make study participation dangerous, as determined by study physician\n* Diagnosed with an acute, severe psychiatric illness\n* Current SCID I-E module diagnosis of benzodiazepine or alcohol abuse\n* Use of alcohol or benzodiazepines in the 30 days prior to study entry, as determined by the Addiction Severity Index\n* Pending legal action that may prohibit or interfere with study participation","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"41 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Child's Head Circumference Measurement (Measured at Birth)","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":null},{"groupId":"OG001","value":"33.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Child's Length of Hospital Stay","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Children Requiring Treatment for Neonatal Abstinence Signs (NAS)","description":"Neonatal abstinence syndrome (NAS) characterized by hyperirritability of the central nervous system and dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory system.11 When left untreated, NAS can result in serious illness (e.g., diarrhea, feeding difficulties, weight loss, and seizures) and death.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"PRIMARY","title":"Child's Peak Daily Total NAS Score","description":"NAS was measured with the MOTHER NAS scale, which includes 28 items, 19 of which are used for scoring and medication decisions. Scores can range from 0 to 42, with higher scores indicating more severe withdrawal.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Total Amount of Morphine Sulfate That a Neonate Receives to Treat NAS","description":"Total amount in mg","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Mother's Self-report of Drug Use (Measured Monthly by Time Line Follow Back)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Mother's HIV Risk Behaviors (Measured Monthly by Risk Behavior Assessment)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Mother's Measures of Dose Adequacy and Acceptance Over Time (Measured Weekly by Dose Adequacy Measure)","description":"Pregnant women maintained on an opioid agonist medication may require upward adjustment to their medication during the course of pregnant. The Dose Adequacy Measure represented a recordation of dosing adjustments during the course of the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Mother's Psychosocial Functioning at Delivery as Measured by the Addiction Severity Index Psychosocial Index Score","description":"The Addiction Severity Index is a structured clinical interview that assesses problem severity in 7 areas of functioning: alcohol use, drug use, medical, legal, employment, psychosocial, and psychiatric status. Each area of functioning yields a composite scale score between 0 and 1, with higher scores indicating greater problem severity in that area. Only the psychosocial index was examined in this study.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".014","spread":null},{"groupId":"OG001","value":".088","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":89},"commonTop":["gastrointestinal","respiratory","musculoskeletal","neuromuscular","hematopoietic or lymphatic symptoms"]}}}